Ainnocence, founded in 2021 in Bay Area, California, is a next-generation biotech company with a radical AI software system designed to minimize drug discovery risks and costs by up to 80%. Its fast-evolving platform delivers lightning-fast virtual screening and multi-objective pharmacological optimization for small molecules, antibodies, and other complex therapeutic modalities. With a computational capacity to screen up to 10 Billion protein sequences or chemical compounds within hours, Ainnocence significantly reduces discovery time and costs while achieving exceptionally high wet-lab hit rates. The AI system enable drug design to tackle previously undruggable or 3D structure unknown targets to achieve a 75% expanded therapeutic space.
Our groundbreaking AI system empowers biotech and pharmaceutical companies to boldly pursue ambitious ‘moonshot’ cures, reshaping the future of R&D by accelerating the discovery of life-saving therapies with unprecedented speed, lower costs, and higher success rates. We envision AI as a catalyst for innovation, driving a better world through transformative advancements in healthcare.
